D2 receptor binding after 4 weeks of continuous infusion of antipsychotic drugs
| Brain Region | Controls | Olanzapine | Risperidone | Quetiapine | Clozapine 2-a | Fluphenazine 2-a |
|---|---|---|---|---|---|---|
| Cerebral cortex | ||||||
| Medial-prefrontal | 18.4 ± 0.6 (100) | 30.8 ± 1.0 (167)* | 24.7 ± 1.3 (134)* | 20.1 ± 0.5 (109) | (160)* | (146)* |
| Dorsolateral | 13.0 ± 0.7 (100) | 14.9 ± 0.5 (107) | 12.6 ± 0.4 (91) | 14.7 ± 0.5 (106) | (111) | (92) |
| Nucleus accumbens | 153.3 ± 7.2 (100) | 210.4 ± 14.4 (137)* | 196.8 ± 9.8 (128)* | 164.4 ± 6.3 (107) | (103) | (167)* |
| Caudate-putamen | ||||||
| Medial | 169.9 ± 8.5 (100) | 244.9 ± 21.7 (144)* | 215.9 ± 12.6 (127)* | 168.1 ± 11.1 (99) | (104) | (126)* |
| Lateral | 224.5 ± 12.1 (100) | 311.4 ± 16.3 (139)* | 276.2 ± 18.0 (123)* | 231.4 ± 17.4 (103) | (109) | (117)* |
| Hippocampus | 35.3 ± 1.0 (100) | 54.4 ± 3.5 (153)* | 46.0 ± 2.1 (130)* | 37.5 ± 2.6 (106) | ||
| Entorhinal cortex | 15.1 ± 1.0 (100) | 16.4 ± 1.1 (108) | 15.4 ± 1.2 (102) | 16.9 ± 0.4 (112) |
Data are mean ± S.E.M. values for binding [fmol/mg of tissue and (percentage of control)], determined by quantitative autoradiography following continuous subcutaneous infusion of vehicle or antipsychotic drugs for 4 weeks, with significant differences from controls indicated in bold (* p < 0.05, N = 7 rats/group), all as described under Experimental Procedures.
↵2-a Data (percentage of control) for clozapine (40 mg/kg/day) and fluphenazine (1 mg/kg/day) were determined previously (Tarazi et al., 1997c) and are shown for comparison.